Company news
Suzhou Ribo Life Science Co. Ltd. news
Latest news releases, newest first.
Next Day Disclosure Return
November 3, 2026
Next Day Disclosure Return
October 29, 2026
Next Day Disclosure Return
October 27, 2026
Next Day Disclosure Return
October 23, 2026
Next Day Disclosure Return
October 22, 2026
Next Day Disclosure Return
October 21, 2026
Discloseable and connected transaction acquisition of the remaining 49.71% shareholding in a subsidiary involving the issue of consideration shares under Specific mandate; and proposed change of registered capital and amendments to the articles of association
October 19, 2026
Voluntary announcement - phase i clinical trial application submission of RBD3133 injection for overweight and obesity
October 7, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 7, 2026
2026 Interim report
September 21, 2026
Next Day Disclosure Return
September 16, 2026
Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI
May 12, 2026
Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)
May 6, 2026
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
February 11, 2026
Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange
January 9, 2026